Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases
Leon A. Adams, Quentin M. Anstee, Herbert Tilg, et al.
Gut (2017) Vol. 66, Iss. 6, pp. 1138-1153
Open Access | Times Cited: 995

Showing 1-25 of 995 citing articles:

From NASH to HCC: current concepts and future challenges
Quentin M. Anstee, Helen L. Reeves, Elena Kotsiliti, et al.
Nature Reviews Gastroenterology & Hepatology (2019) Vol. 16, Iss. 7, pp. 411-428
Closed Access | Times Cited: 1147
Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
David Højland Ipsen, Jens Lykkesfeldt, Pernille Tveden‐Nyborg
Cellular and Molecular Life Sciences (2018) Vol. 75, Iss. 18, pp. 3313-3327
Open Access | Times Cited: 1114
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
Thomas G. Cotter, Mary E. Rinella
Gastroenterology (2020) Vol. 158, Iss. 7, pp. 1851-1864
Closed Access | Times Cited: 1000
New trends on obesity and NAFLD in Asia
Jian-Gao Fan, Seung Up Kim, Vincent Wai‐Sun Wong
Journal of Hepatology (2017) Vol. 67, Iss. 4, pp. 862-873
Open Access | Times Cited: 977
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies
Norbert Stefan, Hans‐Ulrich Häring, Kenneth Cusi
The Lancet Diabetes & Endocrinology (2018) Vol. 7, Iss. 4, pp. 313-324
Closed Access | Times Cited: 737
Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study
Eduardo Vilar‐Gómez, Luis Calzadilla Bertot, Vincent Wai‐Sun Wong, et al.
Gastroenterology (2018) Vol. 155, Iss. 2, pp. 443-457.e17
Open Access | Times Cited: 672
Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
Amedeo Lonardo, Fabio Nascimbeni, Alessandro Mantovani, et al.
Journal of Hepatology (2017) Vol. 68, Iss. 2, pp. 335-352
Closed Access | Times Cited: 626
Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women
Lesley Hoyles, José Manuel Fernández‐Real, Massimo Federici, et al.
Nature Medicine (2018) Vol. 24, Iss. 7, pp. 1070-1080
Open Access | Times Cited: 586
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2020) Vol. 69, Iss. 9, pp. 1691-1705
Open Access | Times Cited: 581
Advancing the global public health agenda for NAFLD: a consensus statement
Jeffrey V. Lazarus, Henry E. Mark, Quentin M. Anstee, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 19, Iss. 1, pp. 60-78
Open Access | Times Cited: 529
Direct effects of thyroid hormones on hepatic lipid metabolism
Rohit A. Sinha, Brijesh Kumar Singh, Paul M. Yen
Nature Reviews Endocrinology (2018) Vol. 14, Iss. 5, pp. 259-269
Open Access | Times Cited: 507
Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis
Alessandro Mantovani, Christopher D. Byrne, Enzo Bonora, et al.
Diabetes Care (2018) Vol. 41, Iss. 2, pp. 372-382
Open Access | Times Cited: 501
NAFLD and cardiovascular diseases: a clinical review
Philipp Kasper, Anna Martin, Sonja Lang, et al.
Clinical Research in Cardiology (2020) Vol. 110, Iss. 7, pp. 921-937
Open Access | Times Cited: 464
Complications, morbidity and mortality of nonalcoholic fatty liver disease
Alessandro Mantovani, Eleonora Scorletti, Antonella Mosca, et al.
Metabolism (2020) Vol. 111, pp. 154170-154170
Open Access | Times Cited: 443
Determinants of fibrosis progression and regression in NASH
Detlef Schuppan, Rambabu Surabattula, Xiaoyu Wang
Journal of Hepatology (2017) Vol. 68, Iss. 2, pp. 238-250
Closed Access | Times Cited: 419
A global view of the interplay between non-alcoholic fatty liver disease and diabetes
Norbert Stefan, Kenneth Cusi
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 4, pp. 284-296
Closed Access | Times Cited: 402
Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis
Alessandro Mantovani, Alessandro Csermely, Graziana Petracca, et al.
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 11, pp. 903-913
Open Access | Times Cited: 395
Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus
Giovanni Targher, Amedeo Lonardo, Christopher D. Byrne
Nature Reviews Endocrinology (2017) Vol. 14, Iss. 2, pp. 99-114
Closed Access | Times Cited: 360
NAFLD as a driver of chronic kidney disease
Christopher D. Byrne, Giovanni Targher
Journal of Hepatology (2020) Vol. 72, Iss. 4, pp. 785-801
Open Access | Times Cited: 349
Nonalcoholic Fatty Liver Disease and the Heart
Eric Stahl, Devinder S. Dhindsa, Suegene Lee, et al.
Journal of the American College of Cardiology (2019) Vol. 73, Iss. 8, pp. 948-963
Closed Access | Times Cited: 337
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
Jan W. Eriksson, Per Lundkvist, Per‐Anders Jansson, et al.
Diabetologia (2018) Vol. 61, Iss. 9, pp. 1923-1934
Open Access | Times Cited: 324
Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis
Alessandro Mantovani, Gianluigi Zaza, Christopher D. Byrne, et al.
Metabolism (2017) Vol. 79, pp. 64-76
Open Access | Times Cited: 295
Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade
Herbert Tilg, Timon E. Adolph, Alexander R. Moschen
Hepatology (2020) Vol. 73, Iss. 2, pp. 833-842
Open Access | Times Cited: 295
Changing epidemiology, global trends and implications for outcomes of NAFLD
Vincent Wai‐Sun Wong, Mattias Ekstedt, Grace Lai‐Hung Wong, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 3, pp. 842-852
Open Access | Times Cited: 287
Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial
Samer Gawrieh, Mazen Noureddin, Nicole Loo, et al.
Hepatology (2021) Vol. 74, Iss. 4, pp. 1809-1824
Open Access | Times Cited: 265
Page 1 - Next Page

Scroll to top